We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Down more than 10% in 2023, Fools are backing these 5 UK stocks to reverse that – and then some! – in 2024

Five Fools see buying opportunities among these beaten-down shares in the UK stock markets!

Investor looking at stock graph on a tablet with their finger hovering over the Buy button

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

While the FTSE 100 has just about broken even since the turn of the year at the time of writing, and the FTSE 250 is only down by around 2.5%, other UK-listed stocks haven’t fared so well.

However, these Fools remain bullish and are considering either topping up their shareholdings or taking advantage of the recent weakness to start a position in the business!

Should you buy AstraZeneca Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

AstraZeneca

What it does: AstraZeneca is a global pharmaceutical firm operating across areas including oncology, rare diseases, cardiovascular, respiratory and immunology.   

By Ben McPoland. As I write, the AstraZeneca (LSE: AZN) share price is down 10.5% in 2023. However, I’m backing it to rebound strongly next year.

Firstly, the company boasts more than 50 approved drugs on the market across its various categories and is expected to report a healthy uptick in profits next year.

But it’s the future that really excites me. The company’s pipeline is oceanic in its deepness, with some 167 research and development projects. And it has many late stage trails ongoing, targeting large, high-growth markets. Some of these may bear fruit next year.

Of course, some of these could also disappoint in the clinic, which is always a risk. However, the size of the pipeline and a reasonable starting valuation makes me think 2024 could be a strong year.

Finally, brokers are also bullish on the stock and there is a consensus price target of £131. That’s around 30% higher than the current share price of £101, as I write. The stock is on my 2024 buy list.

Ben McPoland does not own shares of AstraZeneca.

Diageo 

What it does: Diageo owns a large range of popular beers, spirits and liquors which it sells in almost 180 countries.  

By Royston Wild. Drinks giant Diageo (LSE:DGE) has collapsed in price during 2023. Concerns over slowing US sales, and how new CEO Debra Crew will address the problem, have rattled investor confidence.  

Fears over an expensive (and image-damaging) legal wrangle with rapper Sean Combs over previous collaborations haven’t helped the mood, either. But I believe the company’s 15% share price decline in 2023 is overdone, and expect it to flip back sharply from current levels. 

It leaves the company on a price-to-earnings (P/E) ratio of around 19 times, well below historical norms. 

I think Diageo is a perfect stock to own in these troubled times. Even if consumer spending remains under pressure, its market-leading labels (like Johnnie Walker whisky and Baileys Irish cream) will remain in high demand. 

In fact, the drinks maker should be able to keep raising prices in the new year to offset ongoing cost pressures. This winning blend helped the company grow organic revenues and pre-tax profit rose 6.5% and 8% respectively in the last financial year (to June 2023). 

Royston Wild owns shares in Diageo.

Glencore

What it does: Glencore is one of the world’s largest natural resource companies with operations across 35 countries.

By Andrew Mackie. In the two years following the Covid crash, Glencore (LSE: GLEN) was one of the best performing shares in the FTSE 100. However, year to date, its share price has dropped 20%. This has presented me with a rare opportunity to top up shares in this one-of-a-kind mining business.

Its unique competitive advantage lies in its diversified business model. It operates across the entire value chain, sourcing, marketing, distributing and recycling commodities.

One of the primary reasons why I continue to invest in mining is because I foresee a supply-demand mismatch on the horizon. Copper will be the poster boy of this story.

Study after study has shown that existing copper reserves and production will not be enough to meet the world’s needs for this electrification metal. Electrical grids across the globe need to expand exponentially to cope with an explosion in the likes of EVs and heat pumps.

As a result, I view Glencore shares as very much as a long-term play. As a cyclical business, prices for what it produces tend to swing wildly and, with it, its share price. But I can stomach short term volatility for the ultimate prize.

Andrew Mackie owns shares in Glencore.

Hargreaves Lansdown

What it does: Hargreaves Lansdown operates the largest retail investment platform in the UK.

By Edward Sheldon, CFAHargreaves Lansdown (LSE: HL.) shares haven’t performed well in 2023. As I write this in early December, they’re down about 15% for the year.

I’m optimistic that they can rebound in 2024, however.

One catalyst for a rebound could be UK interest rate cuts, which I believe are a real possibility next year. These could decrease the appeal of cash savings and increase the appeal of stock market investing.

Another catalyst could be an increased focus on value stocks, which have been out of favour in 2023. Currently, Hargreaves Lansdown has a low valuation. It also sports a huge dividend yield (over 6%).

Of course, there’s no guarantee that the shares will rebound in 2024. If UK investor confidence remains low, the share price could remain depressed.

Eventually though, I think investors will wake up to the long-term growth potential here, and give the stock a higher earnings multiple.

Edward Sheldon owns shares in Hargreaves Lansdown

Watches of Switzerland Group

What it does: Watches of Switzerland Group is a retailer of classic and luxury timepieces.

By Paul Summers. Shares in Watches of Switzerland Group (LSE: WOSG) have followed the same trajectory in 2023 as those of many companies operating in the luxury sector. As the cost of living crisis intensified, revenue ticked lower in the UK and Europe, not helped by the temporary closure of some showrooms for refurbishment. 

I regard recent performance as a healthy (albeit unpleasant) correction for a business whose valuation overheated in the aftermath of the pandemic. Growth prospects remain solid, especially if it can capitalise on the demand for pre-owned timepieces.

We may not have long to wait for a recovery if there’s a drop in interest rates next year. Possibly in anticipation of this, the shares have been steadily rising over November and December.

Considering they still change hands for less than 13 times forward earnings as I type, however, there’s potentially (a lot) more to come. 

Paul Summers has no position in Watches of Switzerland Group

The Motley Fool UK has recommended AstraZeneca Plc, Diageo Plc, and Hargreaves Lansdown Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female couple boarding their plane at the airport to go on holiday.
Investing Articles

Can the Rolls-Royce share price reach £15.97 by the end of August?

The Rolls-Royce share price has had a solid run in the last year. Muhammad Cheema takes a look at whether…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Up 1,200% in 5 years, here’s why Nvidia could still be a brilliant value stock

An exciting new announcement that could reshape the PC industry has just pushed Nvidia stock... well, just about nowhere really.

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

How investing £4.50 a day could set you on the way to a £1,505 monthly second income

How can UK stocks with high dividend yields help investors earn a meaningful second income from the price of a…

Read more »

Investing Articles

Up 103% with a P/E of 261 — is this FTSE 100 stock still worth buying?

One FTSE 100 stock is quietly moving higher while most investors are still looking elsewhere — is the market missing…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

The smart money thinks AI stocks look risky — but is there still a chance to buy?

According to fund managers, the AI trade is getting crowded. But they still seem to think it’s the place to…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Barclays shares are 11% below their 52-week high. Could they be a bit of a bargain to consider?

Overpriced or one of the FTSE 100’s hidden gems? James Beard takes a closer look at how the market is…

Read more »

Stack of one pound coins falling over
Investing Articles

Down 65% but yielding 6.7% – is this beaten-down UK stock now a generational bargain?

Harvey Jones says this UK stock is one of the worst FTSE 100 performers but there are sound reasons to…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Is this FTSE stock really 46% undervalued?

Analysts reckon this FTSE stock should be worth nearly 50% more. James Beard considers why there’s so much positivity surrounding…

Read more »